Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07249788
PHASE4

Resmiterom Efficacy & Safety in Patients With MASH

Sponsor: Nabiqasim Industries (Pvt) Ltd

View on ClinicalTrials.gov

Summary

Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Official title: Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

165

Start Date

2025-10-17

Completion Date

2026-12-31

Last Updated

2025-12-03

Healthy Volunteers

No

Interventions

DRUG

Resmetirom

1st FDA approved MASH therapy

Locations (1)

Liver transplant center, Holy family hospital

Rawalpindi, Punjab Province, Pakistan